Canada’s New Marijuana Medical Access Program

On June 10, 2013 the Minister of Health released the new regulations that will govern access to cannabis for medical purposes in Canada. The regulations are the result of consultations over the past two years and introduce significant changes to the program. The regulations eliminate previous requirements that patients submit an application to Health Canada requesting authorization to possess cannabis. Instead they must seek a document from their physicians that they would then present to a licensed producer. Though this move could potentially streamline access to cannabis for medical purposes, the Canadian Medical Association has released a report that suggests that many physicians believe they do not know enough about the benefits and risks of cannabis to “prescribe” it to their patients for medical purposes. The irony of this situation is that the prohibition of cannabis has limited the amount of research into its medical benefits (though research is increasing).

In addition, the new rules eliminate personal and designated production by individuals in their homes by March 31, 2014. This means that current options to access cannabis for medical purposes will be replaced by regulated and commercial Licensed Producers and medical cannabis dispensaries remain excluded from the supply chain by these new regulations. Many patients produce their own cannabis in order to access strains that they have found to be helpful. Maintaining one’s own garden is also cost-effective. Even the government’s own regulatory impact statement notes that the cost of medical cannabis will go up with the new rules. These cost increases could potentially act as further barriers to accessing cannabis for medical purposes.

The exclusion of medical cannabis dispensaries from the supply chain is counterintuitive. The personnel working in these dispensaries are experts on using cannabis to treat a variety of medical conditions. Dispensaries also offer a range of patient-centred services and supports that help challenge the isolation many patients experience. And Canadian medical cannabis dispensaries have developed a rigorous accreditation program to ensure consistency in both the quality of their services and the products dispensed at these sites. Without dispensaries, patients will have to submit their doctor’s authorization to a licensed commercial producer and then receive their medication by courier, without the supports accorded by face-to-face consultations.

The odd thing about the new rules is that they introduce a fully commercialized route of access to cannabis for medical purposes while keeping the overall prohibition of this drug fully in place. Indeed some of the provisions for producers of cannabis for medical purposes may serve as a model for production of cannabis for a legal, regulated market. At the same time, the requirements for licensed producers are quite strict and could make it very difficult for small growers to transition to this new regime. It is also unclear how many licensed producers will be approved by Health Canada. This later point is key for patients who want to able to access a range of strains of cannabis.

All in all, these new rules will likely result in new barriers to accessing cannabis for medical purposes and will end up costing patients more money over the long-term.

– Connie Carter & Lynne Belle-Isle


About CDPC

We are an independent civil society network of organizations and individuals working to improve Canada’s drug policies. Staff occasionally re-post important articles and curate this space with guest bloggers from our network.

Sign up for latest news and updates


This is a guest blog provided by Nazlee Maghsoudi. The Canadian Drug Policy attended HR17 and we are pleased to share this account of the conference.   With growing international attention…

insite vigil poem by the late Bud Osborn March 1, 2017

Last week, for the National Day of Action for the Overdose Crisis, we marched with 922 feathers, one for every life lost in BC in 2016. Our Executive Director, Donald MacPherson,…

In Memory of Raffi Balian February 22, 2017

Raffi Balian passed away on February 16, 2017 Raffi was one of the founding members of the Canadian Drug Policy Coalition (CDPC). He was very excited that the founding group…

How to Help the Overdose Crisis December 21, 2016

As 2016 comes to a close, we reflect on the tragedy that continues to unfold in Canada; the unprecedented numbers of deaths from drug overdoses this year. At CDPC, we…

World AIDS Day 2016 – Three Papers To... December 1, 2016

World AIDS Day 2016 is on December 1st. View three important publications relating HIV/AIDS to harm reduction and drug policy. We will continue to work towards the equitable, safe and dignified treatment…

We’ve Been Here Before – Overdose Deaths in... November 24, 2016

Former BC Chief Coroner Vince Cain, in his report on British Colombia’s opioid overdose catastrophe in the nineties, conducted a thorough analysis of the problem we were facing then. Among…